In a phase 2b trial, around half of patients taking the novel calcineurin inhibitor at a dose of 23.7 mg twice daily achieved complete remission at 48 weeks.
End-stage renal disease is 5-fold more likely to develop in patients with 3 or more infection-related hospitalizations versus none.
The primary outcome was reduction in proteinuria, as measured by protein-to-creatinine (P:C) ratio in a 12-hour urine collection, at 24 weeks compared with baseline.
Ongoing studies are now looking at pharmacogenetics when comparing mycophenolate mofitil and cyclophosphamide for treating lupus nephritis.
Chemokines, cytokines, and markers of cellular damage had the most predictive power.
The development of this scale, once further validated, will give clinicians the ability to verify lupus nephritis activity without the need for an invasive kidney biopsy.
Among the findings, researchers found no association between mixed or pure histopathologic features of LN at presentation and rates of complete or partial remission.
Researchers find an increased risk of death among patients.
Athcar gel may be a treatment option for patients with treatment-resistant nephrotic syndrome.
Antimalarial protects against metabolic syndrome, countering steroid effects.
No change in interferon signature in vitamin D-deficient patients, those with vitamin D repletion.
Increased risk of systemic lupus erythematosus, lupus nephritis with copy number loss, not gain.
Urinary red blood cells undermine a composite prediction of renal outcome.
New study also provides evidence that an early proteinuria decrease is a strong predictor of good long-term outcome.
Minority race/ethnicity and lack of private insurance associated with inadequate care in U.S.
The risk of end-stage renal disease in patients with systemic lupus erythematosus may even be declining, but outcomes differ by race.
The condition appears to be associated with high hospitalization and death rates, researchers reported.
Half of those lupus nephritis patients taking three medications achieved full remission.
A plant-based compound could provide a new treatment for lupus nephritis with fewer side effects.
Large study looked at matched pairs of lupus patients with renal disease starting dialysis with hemodialysis or peritoneal dialysis.
With systemic lupus erythematosus, kidney disease reduces life expectancy an average of 15 years
Predictors of moderate-severe SLE flare at week 52 identified using three indicators
A 50% or greater reduction in proteinuria after six months of treatment for severe lupus nephritis predicted better 15-year renal survival.
Do you think patients with lupus nephritis can be good renal transplant candidates if their disease has been quiescent for at least one year?February 15, 2013
In a recent study researchers examined transplant outcomes in patients with lupus nephritis who had no clinical evidence of disease in the year prior.
Lupus nephritis patients can be good candidates if their disease is quiescent for at least one year prior to surgery.
Genetic changes may partly explain why African-Americans with lupus are up to five times more likely develop end-stage kidney disease.
SLE patients with renal failure often continue to experience flares, but most commonly these are serologic rather than clinical.
If a lupus patient has never had renal disease, pregnancy, in and of itself, is not likely to increase that risk.
Renal and Urology News Articles
- RP for Prostate Cancer May Not Offer Survival Advantage
- Active Surveillance for Intermediate-risk Prostate Cancer Challenged
- Ferritin Spike Soon After Hemodialysis Initiation Ups Mortality Risk
- Training Staff in HIPAA Regulations
- Increased Mortality in CKD Pts With Impaired LV Global Longitudinal Strain
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)